Biothera

Biothera Pharmaceuticals Inc. is a mid clinical-stage biotechnology company advancing Imprime PGG, a first-in-class, systemically administered beta glucan PAMP (pathogen associated molecular pattern). Imprime PGG acts as an immunological “ignition switch,” triggering a robust, coordinated immune response to enhance the anti-tumor effects of checkpoint inhibitors (PD-1, PD-L1 antibodies), anti-angiogenic antibodies (e.g., Avastin®), and tumor-targeting monoclonal antibodies (e.g., Erbitux®). Imprime PGG is the most advanced PAMP in immune-oncology, with a strong safety profile in 400+ patients and established proof of concept in single arm and randomized Phase 2 studies in non-small cell lung cancer (NSCLC), colorectal cancer (mCRC), and chronic lymphocytic leukemia (CLL). Imprime PGG has broad intellectual property protections, with more than 100 issued and pending patients in the US and internationally. Biothera Pharmaceuticals is a subsidiary of Biothera Holding Corp., a privately held company.
Company growth
Type
Private
HQ
Eagan, US
Founded
1997
Size (employees)
81 (est)+2%
Biothera was founded in 1997 and is headquartered in Eagan, US

Key People at Biothera

Richard Mueller

Richard Mueller

CEO
William Gacki

William Gacki

CFO
Steven Karel

Steven Karel

COO
Myra Patchen

Myra Patchen

CSO
Daniel Conners

Daniel Conners

Founder, President & Chairman

Biothera Office Locations

Biothera has office in Eagan
Eagan, US

Biothera Metrics

Biothera Summary

Founding Date

1997

Total Funding

$5.09 M

Latest funding size

$1.59 M

Time since last funding

about 2 years
We estimate that Biothera's latest funding round in December 2014 was $1.59 M. In total, Biothera has raised $5.09 M
We estimate that Biothera's current employees are approximately 42% female and 58% male.

Biothera Online Presence

Biothera News

Biothera Company Life

You may also be interested in